Ozempic vs Pomalyst
Side-by-side drug price comparison from Medicare Part D data
Verdict
Ozempic costs 96% less per claim than Pomalyst ($685.00 vs $17250.00). Neither drug has a generic alternative available. Total Medicare spending: Ozempic at $5.0B vs Pomalyst at $3.3B.
| Metric | Ozempic | Pomalyst |
|---|---|---|
| Avg Cost per Claim Average cost Medicare pays per prescription claim | $685* | $17,250 |
| Total Medicare Spending Total Medicare Part D spending on this drug | $5.0B | $3.3B |
| Total Claims | 7,240,000 | 192,000 |
| Year-over-Year Change Price change from prior year (lower is better for patients) | 72.5% | 4.7%* |
| Generic Available | No | No |
| Condition | Diabetes | Cancer |
| Total Beneficiaries | 1,180,000 | 18,000 |
Ozempic costs 96% less per claim than Pomalyst ($685.00 vs $17250.00). Neither drug has a generic alternative available. Total Medicare spending: Ozempic at $5.0B vs Pomalyst at $3.3B.
Explore More
The side-by-side above pulls the CMS Medicare Part D Drug Spending data data for both entity A and entity B. What follows is the interpretation — which specific axes carry the most weight for entity A versus entity B, and which differences are large enough to influence a real decision.
Practical use of the comparison: read the data above, then drill into the individual entity A and entity B detail pages for the underlying breakdown. A pairwise comparison answers the relative question; the per-entity pages answer the absolute question.
Source: CMS Medicare Part D Spending, 2026.